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Abstract
Background: The investigational medicinal product GKT137831 is a selective inhibitor of NOX 1 and 4 isoforms of
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes, which has the potential to
ameliorate diabetic kidney disease. An investigator-initiated, double-blind, randomised, placebo-controlled,
multicentre phase 2 clinical trial started recruitment in December 2017, with the aim of evaluating the efficacy and
safety of GKT13783, in adults with type 1 diabetes mellitus and persistently elevated urinary albumin excretion over
a period of 48 weeks.
Methods/design: The trial is currently recruiting in Australia and New Zealand, with recruitment expected to end
on 30 June 2020. The primary outcome measure of the trial is the urinary albumin excretion level measured at 48
weeks of treatment. This statistical analysis plan presents an update to the published trial protocol and provides a
comprehensive description of the statistical methods that will be used for the analysis of the data from this trial. In
doing so, we follow the “Guidelines for the content of statistical analysis plans in clinical trials” to support
transparency and reproducibility of the trial findings.
Discussion: With the use of this prior statistical analysis plan, we aim to minimise bias in the reporting of the
findings of this trial, which evaluates the investigational medicinal product GKT137831. The results of the trial are
expected to be published in 2022.
Trial registration: ANZCTR registry: ACTRN12617001187336. Registered on 14 July 2017.
Universal Trial Number: U1111-1187-2609; Protocol number: T1DGKT137831; Genkyotex trial number: GSN000241.
Keywords: Statistical analysis plan, Randomised controlled trial, GKT137831, Albuminuria, Type 1 diabetes
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: alyshad@unimelb.edu.au
1Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia
2The University of Melbourne, Parkville, VIC 3010, Australia
Full list of author information is available at the end of the article
De Livera et al. Trials          (2020) 21:459 
https://doi.org/10.1186/s13063-020-04404-0
Introduction
The kidney is a major target organ of microvascular
damage in type 1 diabetes mellitus. Diabetic kidney
disease affects 14–31% of people with type 1 diabetes
mellitus [1], with studies showing that there is an urgent
need for innovative treatment strategies to prevent,
arrest, treat and reverse diabetic kidney disease [2].
The active investigational medicinal product evaluated
in this study, a NOX1/4 inhibitor known as GKT137831
or setanaxib, has the potential to ameliorate diabetic
kidney disease, and has been previously evaluated in
people with type 2 diabetes mellitus and overt nephropa-
thy (NCT02010242). The present trial is a separate study
in people with albuminuria and type 1 diabetes mellitus
[2] with a longer treatment duration and a higher dose.
The overall objective of this trial is to evaluate the effi-
cacy and safety of GKT137831 400 mg, taken twice a
day, compared to placebo in adults with type 1 diabetes
mellitus and elevated urinary albumin excretion.
Here, we provide a detailed description of the statis-
tical methods that will be used for analysing the data
obtained from this trial. In doing so, we followed the
Guidelines for the content of statistical analysis plans in
clinical trials [3], and care was taken to include the
necessary information and sections as per these guide-
lines. This statistical analysis plan uses the recently pub-
lished study protocol [2]. With the use of this statistical
analysis plan, we aim to minimise reporting bias, sup-
porting both transparency and reproducibility of the trial
findings.
Study methods
Trial design
This is a multicentre, multi-national, phase 2, rando-
mised, double-blind, placebo-controlled clinical trial
with two parallel arms with 1:1 allocation ratio, which
will test the effect of oral GKT137831 400 mg taken
twice a day compared to placebo, on urine albumin to
creatinine ratio, in adults with type 1 diabetes mellitus
and persistent albuminuria despite optimal preceding
standard of care treatment. The trial started recruitment
in December 2017 and the recruitment is expected to
end on 30 June 2020. The treatment period is 48 weeks
with total study duration for the participant of up to 56
weeks. Figure 1 and Table 4 of the protocol [2] describe,
respectively, the timeline for the study, which consists of
10 study visits in total, and the schedule of events.
Randomisation
The randomisation ratio is 1:1 between the active drug
(GKT137831) and placebo control arms, and is stratified
by study centre and urinary albumin–creatinine ratio
(UACR) level with the grouping defined as ≤ 35mg/
mmol or > 35 mg/mmol in female participants and ≤ 25
mg/mmol or > 25mg/mmol in male participants using a
minimisation strategy [4]. Participants will be rando-
mised using a minimisation program integrated into the
Interactive Web Response System, and is accessed live
by sites through the website Randomize.net (see Sect.
3.3 of the protocol [2]).
Sample size
Up to 284 participants in total are expected to be
screened (anticipated screen fail rate up to 50%) with
142 participants each randomised to the treatment and
placebo groups, to achieve 120 participants reaching the
end of the treatment period in total (60 per treatment
group). Sect. 2.5 of the protocol [2] provides details of
the sample size calculations. In brief, the assumptions of
the sample size calculations were the following: mean
UACR of 13.56 mg/mmol in the control arm, difference
between UACR means in the treatment arm of 3.56 mg/
mmol/L (26% reduction in mean UACR in the treatment
arm), equal standard deviations of 7.5 mg/mmol in the
two arms, and within-subject correlation of 0.3. Using
mixed model analysis of covariance with log-
transformed UACR as the outcome, several scenarios
were examined: 60 participants per treatment arm are
required to achieve power > 90% with an alpha level of
0.05 and two-sided hypothesis testing, and 40 partici-
pants per treatment arm are required to achieve power
> 90% with an alpha level of 0.05 and one-sided hypoth-
esis testing.
Trial framework
The primary analysis at the end of this trial will be a
superiority comparison of GKT137831 versus placebo,
where the null hypothesis to be tested for the primary
and secondary endpoint analyses is that the effect of
GKT137831 is no different to placebo and the alterna-
tive hypothesis is that GKT137831 is superior to
placebo. The statistical hypotheses are described in detail
in “Hypotheses” section. For the primary outcome, the
minimal clinically important difference will be consid-
ered according to the sample size calculations in “Sam-
ple size” section; that is as a difference between UACR
means in the treatment arms of 3.56 mg/mmol/L.
Statistical interim analysis
There are no planned interim analyses.
Timing of final analysis
All outcomes will be analysed collectively at the end of
the trial at 48 weeks.
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Timing of outcome measures
The expected visit dates and visit windows are presented
in Figure 1 of the protocol [2], and Table 4 of the proto-
col [2] describes the timing of all outcome measures.
Statistical principles
Confidence intervals and significance level
As the trial investigators have prior clinical knowledge
about the directions of the effects on the endpoint
UACR (primary outcome), midpoint UACR, endpoint
and midpoint estimated glomerular filtration rate (eGFR)
(secondary outcomes), the statistical tests for the
primary and secondary hypotheses will be one-sided. For
these outcomes, based on all the literature to date, there
is no evidence to suggest that the placebo group will
have a better outcome than the intervention group. The
statistical tests for the safety and exploratory analyses
will be two-sided. All the statistical tests will be
performed using a 5% significance level, and we will
report the 95% confidence interval. No adjustment for
multiplicity is needed for the primary hypothesis. Test-
ing for multiple comparisons in the secondary and
exploratory hypotheses will be accounted for by adjust-
ing the p values obtained from these analyses using the
Benjamini-Hochberg method [5].
Adherence and protocol deviations
Definition of adherence
Study drug treatment adherence for each visit interval is
defined as taking at least 80% of the required study drug
dosage. For each participant, this will be based on the
percentage compliance calculated as: percent compli-
ance = (number of capsules taken by the participant/
number of capsules the participant should have taken)
*100%. In this study, the participants will be taking four
capsules twice a day.
Presentation of adherence
The number and percentage of participants taking more
than 80% of the required study drug will be presented by
treatment arm and visit (see Table 1), and the descrip-
tive statistics on the percentage compliance will also be
presented. No formal statistical testing will be
performed.
Definition of protocol deviations
Protocol deviations, “any change, divergence, or depart-
ure from the study design or procedures in the protocol
[2]”, are defined according to the International Confer-
ence on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH)
guideline E3 on Structure and Content of Clinical Study
Reports July1996 [6], classified as either “important” or
“non-important”. Important protocol deviations are devi-
ations that may significantly impact the completeness,
accuracy, and/or reliability of the study data or that may
significantly affect a subject’s rights, safety, or well-being.
Non-adherence as defined in “Definition of adherence”
section will be considered an important protocol
deviation. Deviations that do not fit this definition are
non-important.
Presentation of protocol deviations
Protocol deviations will be summarised by treatment
arm, using the number and percentage of participants
with important and non-important protocol deviations,
and details on the type of deviation. The percentages will
be calculated based on the participants in the intention-
to-treat (ITT) analysis set as the denominator. No
formal statistical testing will be performed. The details
of protocol deviations including adherence will be added
as an aide memoire to Fig. 1.
Analysis populations
The following four analysis sets will be used in the
study.
Main analysis set (ITT analysis set)
The ITT analysis set is the main analysis set that will be
used for evaluating the primary hypothesis, and it
consists of all randomised participants with each partici-
pant retaining their treatment group as originally
allocated by the randomisation procedure.
Modified intention-to-treat analysis set
The modified ITT analysis set consists of participants
who have been randomised and have taken at least one
capsule of investigational product or placebo, with each
participant in the set retaining their treatment group as
originally allocated by the randomisation procedure.
Safety analysis set
The safety analysis set consists of all participants who
have taken at least one capsule of investigational product
Table 1 The number and percentage of participants taking
more than 80% of the prescribed treatment
Visit
numbera
Treatment group
GKT137831 N (%) Placebo, N (%)
4
5
6
7
8
9
10
a Visit number refers to Figure 1 of the protocol [1]
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or placebo and have at least one subsequent safety
assessment, which is described in Sect. 4.2 of the
protocol [2].
Per protocol (PP) analysis set
The PP analysis set consists of the subset of participants
who completed the 48-week treatment period and do
not have an important protocol deviation.
Trial population
Screen data
At enrolment, the following summaries will be presented
by study centre and overall for all screened participants:
number of participants screened, the number of
recruited participants, the number of screened and
eligible participants who are not recruited, the reason
for non-recruitment, and the number of recruiting days.
Eligibility criteria
Participant inclusion and exclusion criteria are presented
in Tables 2 and 3 of the protocol [2], respectively. The
participants with type 1 diabetes mellitus need to have
persistent albuminuria, documented abnormal UACRs
in the preceding 24 months before enrolment in the trial,
already be receiving standard of care therapy for albu-
minuria, and have well-controlled blood pressure and
HbA1c. Participants are excluded if there is occurrence
within 13 weeks before screening of recent changes in
medications that may alter albumin excretion or eGFR,
or certain procedures that may potentially affect kidney
function, or acute kidney injury.
Recruitment
The trial profile will be illustrated using a flow diagram
based on the Consolidated Standards of Reporting
Trials) 2010 (CONSORT) [7] as shown in Fig. 1. The
Fig. 1 A flow diagram of the trial based on Consolidated standards of reporting trials (CONSORT) 2010
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following information will be provided in the diagram
summarizing the number of participants who are eligible
at screening, not eligible at screening (with reasons pro-
vided), eligible and randomised, eligible but not rando-
mised (with reasons provided), received the randomised
allocation, did not receive the randomised allocation
(with reasons provided), withdrawals/lost to follow-up
(with reasons provided - see “Withdrawals/follow-up”
section), randomized and included in the primary ana-
lysis, and randomised and excluded from the primary
analysis (with reasons provided).
Withdrawals/follow up
The number of participants at each level of withdrawal
will be documented and the timing of withdrawals will
be presented in the CONSORT diagram in Fig. 1, cate-
gorized as (1) withdrawn from the intervention but con-
tinued with follow up, (2) withdrawn from follow up but
allowed data collected to date to be used, (3) withdrawn
from follow up and withdrawn consent for data collected
to date to be used, and (4) lost to contact/follow up.
Baseline participant characteristics
The characteristics of the participants, will be sum-
marised by study arm and overall at baseline using
summary statistics as shown in Table 2. Continuous
variables will be summarised by the appropriate central
tendency and dispersion measures, using either mean
and standard deviation (SD) or median and 25th–75th
percentile. Categorical data will be summarised using
frequencies and percentages. The frequencies and
percentages of missing values will be reported for all
variables.
Analysis
Outcome definitions
The outcome measures of the GKT137831 trial can be
divided into primary, secondary, exploratory, pharmaco-
kinetics, and safety outcome measures. This document
focuses on the primary, secondary, exploratory, and
safety outcomes. Pharmacokinetics assessments will be
reported elsewhere.
Table 2 The baseline characteristics of the participants by intervention, placebo groups and overall
Baseline characteristic Intervention
(GKT137831)
group (n = xxx)
Placebo group
(n = xxx)
Percentage
standardised
difference
Overall (n = xxx)
Values Missing, n (%) Values Missing,
n (%)
Values Missing,
n (%)
Urine albumin–creatinine ratio (UACR) (log-transformed)
Mean (standard deviation (SD))
Estimated glomerular filtration rate (eGFR) (log-transformed)
Mean (SD)
Gender
Male, n (%)
Female, n (%)
Age (years),
Mean (SD)
Ethnicity
xx, n (%)
Other, n (%)
Clinical variables
Systolic blood pressure (mmHg), mean (SD)
Diastolic blood pressure (mmHg), mean (SD)
Use of angiotensin-converting-enzyme inhibitor (ACEi), n (%)
Use of angiotensin II receptor blocker (ARB), n (%)
Body mass index (kg/m2), mean (SD)
Duration of diabetes mellitus at baseline (years), mean (SD)
Glycated haemoglobin (HbA1c %), median (25th–75th percentile)
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Primary outcome measure
The primary outcome measure of the trial is the urinary
albumin excretion level measured by the urine albumin–
creatinine ratio (UACR) in milligrams per millimole at
the end of the treatment (endpoint UACR), and is
defined as the geometric mean of four UACR values,
which consists of the two consecutive, daily, first void
UACR values at 46 weeks of treatment and the two con-
secutive, daily, first void UACR values at 48 weeks of
treatment. Baseline UACR is defined as the geometric
mean of four UACR values, which consists of the two
consecutive, daily, first void UACR values at 2 weeks be-
fore randomisation and the two consecutive, daily, first
void UACR values at randomisation. In the statistical
analyses, endpoint UACR will be adjusted for baseline
UACR (see “Primary hypothesis” section).
Secondary outcome measures
The secondary outcome measures of the trial are the
following:
Midpoint urine albumin–creatinine ratio The urinary
albumin excretion level at the midpoint of the treatment
period measured by the urine albumin–creatinine ratio
(midpoint UACR), defined as the geometric mean of the
two consecutive, daily, first void UACR values taken at
the midpoint of treatment at 24 weeks of treatment.
Endpoint estimated glomerular filtration rate The
eGFR at the end of the treatment period at 48 weeks,
measured in millilitres per minute relative to body sur-
face area (endpoint eGFR), and is defined as the geomet-
ric mean of eGFR at week 46 of treatment and the eGFR
at week 48 of treatment. Baseline eGFR is defined as the
geometric mean of the eGFR at 2 weeks before random-
isation and the eGFR at randomisation.
Midpoint estimated glomerular filtration rate The
eGFR at the midpoint of the treatment period at 24
weeks, measured in millilitres per minute relative to
body surface area (midpoint eGFR), and is defined as the
log-transformed eGFR values obtained at week 24 of
treatment.
Exploratory outcome measures
The exploratory outcome measures obtained at the end
(at 48 weeks) of the treatment period are presented in
Sect. 4.2.5 of the protocol [2] and are summarised in
Supplementary Table 1. In the statistical analyses, the
endpoint exploratory outcome measures will be adjusted
for their baseline values taken at randomisation (see “Ex-
ploratory analyses” section).
Safety outcome measures
The key safety outcome measures are treatment-
emergent adverse events and abnormal laboratory
analytes as defined in the protocol [1] Sect. 10.4.4.2 and
10.4.4.3, respectively. All safety outcome measures are
given in Supplementary Table 2 along with references to
the sections where they are defined in the protocol [1].
Hypotheses
Primary hypothesis
The null hypothesis is that the population mean of the
endpoint UACR in the intervention group is the same as
that in the placebo group (after adjustment for baseline
UACR). The alternative hypothesis is that the population
mean of the endpoint UACR is lower in the intervention
group, compared to that in the placebo group (after
adjustment for baseline UACR).
Secondary hypotheses
Midpoint urine albumin–creatinine ratio The null hy-
pothesis is that the population mean of the midpoint
UACR in the intervention group is the same as that in
the placebo group (after adjustment for baseline UACR).
The alternative hypothesis is that the population mean
of the midpoint UACR is lower in the intervention
group, compared to that in the placebo group (after ad-
justment for baseline UACR).
Endpoint estimated glomerular filtration rate The
null hypothesis is that the population mean of the end-
point eGFR in the intervention group is the same as that
in the placebo group (after adjustment for baseline
eGFR). The alternative hypothesis is that the population
mean of the endpoint eGFR is higher in the intervention
group, compared to that in the placebo group (after ad-
justment for baseline eGFR).
Midpoint estimated glomerular filtration rate The
null hypothesis is that the population mean of the mid-
point eGFR in the intervention group is the same as that
in the placebo group (after adjustment for baseline
eGFR). The alternative hypothesis is that the population
mean of the midpoint eGFR is higher in the intervention
group, compared to that in the placebo group (after ad-
justment for baseline eGFR).
Exploratory concepts
The exploratory outcomes (summarised in Supplemen-
tary Table 1) taken at the end of the treatment period
will be compared between the treatment and placebo
groups (adjusting for the values taken at the beginning
of the treatment). These will be carried out as explora-
tory analyses to inform future research directions.
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Safety objectives
The safety objectives are to assess the effects of the
GKT137831 compared to placebo on the key safety
outcome measures (treatment-emergent adverse events
and abnormal laboratory analytes) and the other safety
outcome measures defined in “Safety outcome measures”
section.
Analysis methods
Primary analyses
Main analysis model The main analysis will be based
on the ITT analysis set. The analysis model will be a
linear mixed effects model with endpoint UACR (log-
transformed) as the outcome, a categorical variable
indicating the allocated grouping structure (intervention
versus placebo) as the exposure, and a random effect
term to account for the study centre variability. The
model will incorporate other covariates as discussed in
“Covariate adjustment” section. The results from this
analysis will be summarised in Table 3.
Covariate adjustment The main analysis model de-
scribed in “Main analysis model” section will include
(log-transformed) baseline UACR as a covariate. To as-
sess potential baseline covariate imbalance, the partici-
pant characteristics at baseline described in “Baseline
participant characteristics” section will be compared be-
tween the intervention and placebo arms. Instead of
using hypothesis testing for this purpose due to its de-
pendence on sample size and emphasis on statistical sig-
nificance, the standardized differences in means or
proportions [8] will be used. The main analysis model
will also include the baseline variables that have values
of 10% or greater, in the magnitude of the percentage
standardised differences, as covariates.
Checking assumptions in statistical models The as-
sumptions of linearity between the explanatory variables
and the outcome, constant variance and independence
of the errors, and normality of the error distribution will
be checked using plots of observed values versus pre-
dicted values, residuals versus predicted values, residuals
versus individual independent variables, and normal
probability plots. These plots will also be used to detect
any outliers.
Alternative methods to be used if distributional
assumptions do not hold The UACR levels used in
the analysis model will be log-transformed. However,
alternative transformations will be considered in the
cases where the assumptions of constant variance or
normality of the error distribution is violated. Non-
linear terms will be incorporated to account for any
non-linearity between the explanatory variables and
the outcome. If it is verifiable that any of the outliers
are due to data that are incorrectly measured or reg-
istered, these outliers will be removed. The remaining
outliers will be accommodated using robust estima-
tion of linear mixed effects models [9].
Subgroup analyses Potential effects of the following
pre-specified subgroups on the endpoint UACR levels
will be tested using the model described for the main
analysis in “Main analysis model” section extended to in-
clude the subgroup and subgroup by treatment
Table 3 Primary and secondary results of the GKT137831 trial
Outcome Analysis Mean (standard deviation) Estimated
mean
differencea
95%
Confidence
Interval
P value
Intervention (GKT137831)
group (n = xxx)
Placebo group
(n = xxx)
Primary Endpoint UACR Intention to treat (ITT)
modified ITT
Per protocol (PP)
Secondary Midpoint UACR Intention to treat (ITT)
modified ITT
Per protocol (PP)
Endpoint eGFR Intention to treat (ITT)
modified ITT
Per protocol (PP)
Midpoint eGFR Intention to treat (ITT)
modified ITT
Per protocol (PP)
UACR urine albumin: creatinine ratio, eGFR estimated glomerular filtration rate
a In the intervention group compared to placebo
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interactions: (1) gender, (2) baseline age group (younger
than the median and equal to or older than the median),
(3) duration of diabetes mellitus at baseline (shorter than
the median and equal to or longer than the median dur-
ation), (4) body mass index (BMI) at baseline (lower
than the median and equal to or higher than the median
value), and (5) glycated haemoglobin (HbA1c) level at
baseline (lower than the median and equal to or higher
than the median value). Likelihood ratio tests will be
used to test for interactions and the results will be pre-
sented on forest plots with the interactions results along-
side. The results will also be presented as outlined in
Table 4.
Missing data methods An investigation of the patterns
of missing data will first be carried out. A summary of
which variables contain missing values, proportion of
missing values in each variable, and patterns and predic-
tors of missingness will be provided. This summary will
then be used to decide on the most appropriate method
to handle missing data. If the missing values only arise
in the dependent variable, no imputation will be carried
out, as the main analysis model, which is a linear mixed
effects model, is robust against the missing-at-random
(MAR) mechanism. However, if the missing values are
present in the covariates, following the trial protocol, if
suitable [10], missing values will be handled using mul-
tiple imputation [11] considering both bias and precision
[12]. The following steps will be undertaken: the missing
data in the analysis set will first be assessed by
calculating the proportion of missing values, investigat-
ing the patterns of missingness in the variables, and
identifying predictors of missingness. Based on this, a
suitable imputation model that typically consists of all
the variables in the analysis model and additional auxil-
iary variables (i.e., the variables that correlate with the
variable with missing values and/or are predictors of
missingness) [13] will be used to generate 50 completed
datasets with imputed values using a fully conditional
specification [14]. If missing values are present in the
composite measures (e.g., endpoint UACR and baseline
UACR, which are overall measures based on multiple
log-transformed UACRs) due to item-level missingness,
multiple imputation will be carried out at the item level
[15]. The analysis model will then be used in each com-
pleted dataset and the results will be combined using
Rubin’s rules [16].
Sensitivity analyses The results obtained by using a
mixed effects model of the (log-transformed) endpoint
UACR with the allocated grouping structure as the ex-
posure, a random effect term to account for the study
centre variability, only incorporating (log-transformed)
baseline UACR as a covariate without additional baseline
covariates will also be made available. In addition, the
sensitivity of the results to the decisions made in con-
structing the imputation model, will be investigated
using visualisations of the distributions of imputed and
observed values, standard regression diagnostics [17],
Table 4 Subgroup analyses in the intention-to-treat group, to be presented as forest plots
Subgroup Number (%) Estimated
mean
differencea
95%
Confidence
Interval
P value
Intervention (GKT137831) group (n = xxx) Placebo group (n = xxx)
Sex
Male
Female
Age
<median
≥median
Diabetes mellitus duration
< median
≥median
BMI
<median
≥median
HbA1c
<median
≥median
BMI body mass index, HbA1c glycated haemoglobin
a In the intervention group compared to placebo
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and comparisons with complete case analysis. The
results will be presented as outlined in Fig. 2.
Additional analyses Supplementary analyses will be
completed by repeating the main analysis described in
“Main analysis model” section - “Sensitivity analyses”
section using (1) the modified ITT and (2) the PP
analysis sets, and these results will be reported in the
proposed format.
Secondary analyses
The analyses described in “Main analysis model” section
- “Additional analyses” section will be repeated:
1. For the secondary outcome measures defined in
“Secondary outcome measures” section, and
2. Using the subsets of the GKT137831 group who
have taken the 800 mg/day drug for (a) > 6 months
and (b) > 12 months as the intervention group for
all primary and secondary outcomes defined in
“Primary outcome measure” section and “Secondary
outcome measures” section, respectively.
The results will be reported in the proposed format.
Exploratory analyses
The distributions of the exploratory measures men-
tioned in “Exploratory outcome measures” section will
first be inspected, and then suitably transformed. To in-
spect high-dimensional data, relative log abundance/ex-
pression plots [18] and loadings/scores plots obtained
from principal component analyses will be used [19].
“Remove unwanted variation” (RUV) [20] normalisation
methods will be used to either remove or accommodate
unwanted variation in the high-dimensional data as
appropriate. Systematic patterns in the data will be in-
vestigated using clustering techniques such as the hier-
archical cluster analysis coupled with inspection of
heatmaps. Depending on the distribution of the explora-
tory outcome measure, the differences in the change in
the exploratory outcome measure from baseline to end-
point between the intervention and placebo groups will
be examined using either linear or generalised linear re-
gression models. In these models, the endpoint explora-
tory measure will be used as the outcome and a
categorical variable indicating the allocated grouping
structure (intervention versus placebo) will be used as
the exposure, incorporating exploratory measure at base-
line and other confounding variables as covariates. Test-
ing for multiple comparisons in high-dimensional data
Fig. 2 Forest plot of the mean differences (95% confidence intervals) in the endpoint urine albumin–creatine ratio (UACR) (intervention versus
placebo group)
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will be accounted for, by adjusting the p values obtained
from these analyses using the Benjamini-Hochberg
method to address the false discovery rate [5]. The ex-
ploratory findings from these analyses will inform fur-
ther directions.
Safety analyses
Safety analyses will be based on the safety analysis set
described in “Safety analysis set” section. The safety out-
comes presented in Supplementary Table 2 will be
summarised by group (intervention and placebo). Cat-
egorical variables will be summarised using frequencies
and percentages, and the continuous variables will be
summarised using appropriate central tendency and dis-
persion measures, and presented either as mean and
standard deviation (SD) or median and 25th–75th per-
centile. Percentage standardized differences between the
two groups will be calculated for all variables. A value ≥
10% difference will be taken as a meaningful difference
between the groups. In addition, where possible, a linear
mixed model or a generalised linear mixed model will be
used with the safety measure at the end of the trial as
the outcome, a categorical variable indicating the group
structure (intervention or placebo group) as the expos-
ure, and the safety measure at the beginning of the trial
as a covariate, also accounting for centre variability.
Where appropriate, an estimate of the group effect, 95%
confidence interval and p value will be presented. The
results will be summarised in Table 5.
Conclusion
In this article, we followed the Guidelines for the con-
tent of statistical analysis plans in clinical trials [2] to
provide detailed descriptions of the statistical methods
required for carrying out the statistical analysis of the
GKT137831 trial. The aim of this prior statistical ana-
lysis plan is to minimise reporting bias, supporting both
transparency and reproducibility of the trial findings. All
statistical analyses will be conducted using R (R Founda-
tion for Statistical Computing, Vienna, Austria; lme4
package for R for fitting linear mixed models) and Stata
(StataCorp, College Station, TX, USA). Other software
packages such as SPSS or SAS may be used if necessary.
The results of the trial are expected to be published, and
these results may be used to inform further phase 3
trials for regulatory submission.
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Table 5 Safety analyses results using the safety analysis set
Safety outcome measure Values Percentage
standardized
difference
Estimated
differencea
95%
Confidence
Intervala
P
valueaIntervention (GKT137831) group
(n = xxx)
Placebo group
(n = xxx)
Treatment-emergent adverse events, n (%)
Abnormal laboratory analytes, n (%)
Abnormal physical examination and vital
signs, n (%)
QT corrected electrocardiogram (ECG),
mean (SD)
Treatment-emergent qualitative ECG, n (%)
Concomitant medications, n (%)
Systolic blood pressure (mmHg), mean (SD)
Diastolic blood pressure (mmHg), mean
(SD)
Heart rate (beats per minute), mean (SD)
Weight (Kg), mean (SD)
SD standard deviation
a If feasible to carry out testing; in the intervention group compared to the placebo group
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